CA1048933A - Pharmaceutical preparations for the treatment of hyperuricacidemia - Google Patents
Pharmaceutical preparations for the treatment of hyperuricacidemiaInfo
- Publication number
- CA1048933A CA1048933A CA76253650A CA253650A CA1048933A CA 1048933 A CA1048933 A CA 1048933A CA 76253650 A CA76253650 A CA 76253650A CA 253650 A CA253650 A CA 253650A CA 1048933 A CA1048933 A CA 1048933A
- Authority
- CA
- Canada
- Prior art keywords
- allopurinol
- benzbromaron
- preparation according
- dosage unit
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 5
- 238000011282 treatment Methods 0.000 title abstract description 15
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229960003459 allopurinol Drugs 0.000 claims abstract description 38
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960002529 benzbromarone Drugs 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 239000003979 granulating agent Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 18
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 18
- 229940116269 uric acid Drugs 0.000 description 18
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 6
- 230000029142 excretion Effects 0.000 description 5
- 229950002752 oxipurinol Drugs 0.000 description 5
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000003347 uricostatic effect Effects 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- -1 (2-ethyl-benzofuran-3-yl)-(3,5-dibromo-4-hydroxy-phenyl) Chemical group 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- POOGXHSMLJDKRF-SOOFDHNKSA-N [(3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-2-phosphonooxyoxolan-3-yl] dihydrogen phosphate Chemical compound OC[C@H]1OC(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1O POOGXHSMLJDKRF-SOOFDHNKSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752555609 DE2555609A1 (de) | 1975-12-10 | 1975-12-10 | Pharmazeutisches praeparat zur therapie der hyperurikaemie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1048933A true CA1048933A (en) | 1979-02-20 |
Family
ID=5964014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA76253650A Expired CA1048933A (en) | 1975-12-10 | 1976-05-28 | Pharmaceutical preparations for the treatment of hyperuricacidemia |
Country Status (8)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1698348A4 (en) * | 2003-11-14 | 2008-02-27 | Human Cell Systems Inc | CURATIVE OR PREVENTIVE REMEDY FOR VASCULAR DISORDERS AND HYPERTENSION AND SCREENING METHOD THEREOF |
| EP1721890A4 (en) | 2004-03-01 | 2008-02-27 | Japan Science & Tech Agency | PROCESS FOR THE ALLYLATION OF N-ACYLHYDRAZONES |
| EP1778261A4 (en) * | 2004-07-21 | 2010-08-11 | Univ Florida | COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE |
| JP5844376B2 (ja) * | 2010-10-06 | 2016-01-13 | ジェイファーマ株式会社 | 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物 |
| CN103242272B (zh) * | 2013-05-22 | 2016-01-27 | 合肥医工医药有限公司 | 一种制备苯溴马隆的方法 |
-
1975
- 1975-12-10 DE DE19752555609 patent/DE2555609A1/de active Pending
-
1976
- 1976-05-11 GB GB19223/76A patent/GB1493237A/en not_active Expired
- 1976-05-24 ZA ZA763081A patent/ZA763081B/xx unknown
- 1976-05-24 NL NL7605531A patent/NL7605531A/xx not_active Application Discontinuation
- 1976-05-28 CA CA76253650A patent/CA1048933A/en not_active Expired
- 1976-05-31 BE BE167474A patent/BE842389A/xx not_active IP Right Cessation
- 1976-06-01 FR FR7616454A patent/FR2334362A1/fr active Granted
- 1976-06-29 AU AU15413/76A patent/AU505476B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU1541376A (en) | 1978-01-05 |
| BE842389A (fr) | 1976-09-16 |
| FR2334362B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1979-08-24 |
| ZA763081B (en) | 1977-04-27 |
| DE2555609A1 (de) | 1977-06-30 |
| NL7605531A (nl) | 1977-06-14 |
| FR2334362A1 (fr) | 1977-07-08 |
| GB1493237A (en) | 1977-11-30 |
| AU505476B2 (en) | 1979-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2140266C1 (ru) | Фармацевтическая композиция с регулируемым выделением на основе одной или нескольких фармацевтически приемлемых солей гамма-гидроксимасляной кислоты и способ ее получения | |
| CA2355814C (en) | Pharmaceutical composition for ophthalmic use | |
| US5206264A (en) | Use of disulfiram to prevent cardiovascular damage | |
| SHILS | Experimental human magnesium depletion: I. Clinical observations and blood chemistry alterations | |
| Sorenson et al. | Treatment of rheumatoid and degenerative diseases with copper complexes: a review with emphasis on copper-salicylate | |
| US6191153B1 (en) | Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity | |
| JPH11514629A (ja) | 安定な甲状腺ホルモン含有薬剤 | |
| CA1048933A (en) | Pharmaceutical preparations for the treatment of hyperuricacidemia | |
| US3196078A (en) | Process for combating retinits pigmentosa | |
| Dupuis et al. | Multiple delayed peak lithium concentrations following acute intoxication with an extended-release product | |
| Fine et al. | Malabsorption of frusemide caused by phenytoin | |
| EP0633723B1 (en) | Use of hydriodic acid as an aphrodisiac | |
| KR101086040B1 (ko) | 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체 | |
| HENCH | Gold salts for rheumatoid arthritis | |
| Jacobsen et al. | 4-Methylpyrazole–present status | |
| US3894153A (en) | Method of medical treatment of asthma | |
| Clarke et al. | Confusion and paranoia associated with oral tocainide | |
| US3627886A (en) | Methods of solubilizing coumermycin employing urea, dimethylacetamide or mixtures thereof | |
| CN107789349A (zh) | 治疗阿尔海默氏综合症的药物组合物及其应用 | |
| Mathew et al. | Clonidine overdose in children | |
| CN117298086B (zh) | 索法酮在制备预防和/或治疗nlrp3炎性小体介导的疾病的药物中的应用 | |
| Borreli et al. | The co-operative action of hyaluronidase and urokinase on the isoproterenol-induced myocardial infarction in rats | |
| GB2174905A (en) | Compositions containing reduced glutathione | |
| CN106860472A (zh) | 一种治疗阿尔海默式综合症的药物组合物及其应用 | |
| JPH01180833A (ja) | 血管新生剤 |